O
ADCT icon

OrbiMed’s ADC Therapeutics ADCT Stock Holding History

OrbiMed’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,318,026
Closed -$4.94M – 130
2026
Q1 		$4.94M Sell
1,318,026
-4,504,828
-77% -$17.8M 0.1% 95
2025
Q4 		$20.6M Sell
5,822,854
-84,497
-1% -$343K 0.42% 59
2025
Q3 		$23.6M Hold
5,907,351
– – 0.56% 50
2025
Q2 		$15.8M Sell
5,907,351
-61,100
-1% -$129K 0.4% 46
2025
Q1 		$8.42M Hold
5,968,451
– – 0.2% 66
2024
Q4 		$11.9M Buy
5,968,451
+1,434,650
+32% +$3.75M 0.24% 69
2024
Q3 		$14.3M Buy
4,533,801
+216,977
+5% +$684K 0.26% 73
2024
Q2 		$13.6M Buy
+4,316,824
New +$17.2M 0.27% 66

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OrbiMed's ADCT Position: Q2 2026 in Review

OrbiMed sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 1,318,026 shares — an estimated $4.94M sold.

OrbiMed first reported a position in ADCT in Q2 2024 and held it in 8 quarters. The position peaked at $23.6M in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • OrbiMed reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OrbiMed sold 1,318,026 ADC Therapeutics shares in Q2 2026, an estimated $4.94M.
  • OrbiMed first reported a position in ADC Therapeutics in Q2 2024 and held it in 8 quarters.
  • OrbiMed's ADC Therapeutics position peaked at $23.6M in Q3 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.